Generic Name and Formulations:
Tetrabenazine 12.5mg; 25mg+ (+scored); tabs.
Valeant Pharmaceuticals, Inc
Indications for XENAZINE:
Individualize. Initially 12.5mg once daily in the AM, then 12.5mg twice daily after one week. Titrate slowly at weekly intervals by 12.5mg. Doses of 37.5–50mg/day should be given in a 3 times/day regimen. Max 25mg/dose. Patients who require >50mg/day should be genotyped for CYP2D6. Poor CYP2D6 metabolizers: max 25mg/dose and 50mg/day; extensive and intermediate metabolizers: max 37.5mg/dose and 100mg/day. Concomitant strong CYP2D6 inhibitors: max 25mg/dose and 50mg/day; moderate to weak CYP2D6 inhibitors: not evaluated. Retitrate if therapy interrupted for more than 5 days.
Untreated or inadequately treated depression. Suicidal ideation. Hepatic impairment. During or within 14 days of MAOIs. During or within 20 days of stopping reserpine. Concomitant deutetrabenazine or valbenazine.
Depression and suicidality.
Monitor for emergence or worsening of depression, suicidality, or unusual changes in behavior. History of depression or suicidal ideation. Avoid in congenital long QT syndrome, history of cardiac arrhythmias. Bradycardia. Hypokalemia. Hypomagnesemia. History of breast cancer. Discontinue if neuroleptic malignant syndrome (NMS) occurs. Monitor for parkinsonism, akathisia, restlessness, agitation; may need to reduce dose or discontinue treatment. Poor CYP2D6 metabolizers. Reevaluate periodically. Pregnancy. Nursing mothers.
Vesicular monoamine transporter 2 (VMAT2) inhibitor.
See Contraindications. Avoid concomitant drugs known to prolong QT interval (eg, chlorpromazine, haloperidol, thioridazine, ziprasidone, moxifloxacin, quinidine, procainamide, amiodarone, sotalol). Potentiated by strong CYP2D6 inhibitors (eg, paroxetine, fluoxetine, quinidine); see Adult. Increased risk of parkinsonism, NMS, akathisia with neuroleptics, dopamine antagonists. Additive CNS depression with alcohol, other CNS depressants.
Sedation/somnolence, fatigue, insomnia, depression, akathisia, anxiety/anxiety aggravated, nausea, upper respiratory tract infection; parkinsonism, QTc prolongation, orthostatic hypotension, hyperprolactinemia, extrapyramidal effects, dysphagia, potential for long-term ophthalmologic effects.
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness